Limula receives a FIT Tech Seed loan of CHF 100'000 for its automated cell therapy manufacturing system.

Founded at the end of 2020, Limula has developed a platform for the automated production of personalised therapies. The Tech Seed loan from the Foundation for Technological Innovation (FIT) will help Limula finalise its demonstrator and develop partnerships for a pilot phase.

Cell and gene therapies represent a new paradigm in personalised medicine: they allow a complete remission, both for acute and chronic diseases, based on the reprogramming of immune cells taken from individual patients. Thanks to this autologous approach, these therapies redesign therapeutic interventions from a one-size-fits-all treatment to truly personalised medicine. Over the past decade, clinical trials have repeatedly proven their safety and efficacy, leading to regulatory approvals and the introduction of many life-saving treatments for people who previously had no therapeutic option. However, due to their high cost (between 250,000 and 2 million Swiss francs), mainly due to the complexity of their production, it is impossible to provide cell therapies to all patients who could benefit from them.

Limula was created with the mission of making cell therapies accessible to everyone in need, at a reasonable cost, wherever they are. To achieve this goal, a multidisciplinary team of 7 engineers and biologists has developed an automated solution that allows for a future where these revolutionary therapies will be produced in a decentralised way, directly in the hospital.

Read full press release